Belatacept for heart transplant recipients
Treatments studied
Part of Heart & circulation clinical trials.
This study tests a drug called belatacept, which may help prevent the body from rejecting a new heart. It is given after a heart transplant, and the goal is to see if it works as well as or better than standard anti-rejection medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be receiving your first heart transplant (no other organs at the same time).
- You must have had Epstein-Barr virus (EBV) in the past, which most adults have.
- Your kidney function must be above a certain level before the transplant.
- You must not have had desensitization therapy (treatment to lower antibodies) before the transplant.
- You must not have certain infections like HIV, hepatitis B or C, or active tuberculosis.
- If you are a woman who could become pregnant, you must agree to use birth control and have a negative pregnancy test.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new approach to managing anti-rejection medicines after a heart transplant. It uses special blood tests to see if your immune system is calm, so doctors can safely reduce the medicines and lower side effects.
This study looks at using two anti-rejection medicines (everolimus and a lower dose of a calcineurin inhibitor) after a heart transplant. The goal is to see if this combination is safe and effective for keeping your body from rejecting the new heart, while possibly protecting your kidneys compared to standard treatment.
This trial studies whether belatacept, an anti-rejection medicine given by IV, can work for people receiving their first heart transplant. It aims to see if it prevents rejection safely for patients and whether it fits better than standard approaches for certain candidates.
This trial studies whether belatacept can be used after a heart transplant to help protect kidney function over time. It focuses on people who already have (or are at risk for) worsening kidney function after transplant, while avoiding those with certain infections or rejection concerns.
This trial looks at replacing standard anti-rejection medicines (tacrolimus, a type of CNI, plus mycophenolate and possibly prednisone) with belatacept in adults who have early kidney graft dysfunction 3–12 months after a kidney transplant. It aims to see if belatacept can control rejection and protect kidney function in the right patients.
This trial tests whether belatacept can help prevent damage in kidney transplant recipients who develop new antibodies against their donor kidney. It is for people whose kidney function is still stable, which may allow treatment to slow or stop antibody-related injury.
Hear when a new Heart Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.